Seer to Report First Quarter Financial Results on May 4, 2022
Seer Inc. (NASDAQ: SEER) will report its Q1 2022 financial results on May 4, 2022, followed by a conference call at 2:00 p.m. Pacific Time.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Seer Inc. (NASDAQ: SEER) will report its Q1 2022 financial results on May 4, 2022, followed by a conference call at 2:00 p.m. Pacific Time. The company is known for its innovative Proteograph Product Suite, designed for advanced proteomic analysis. This technology allows for deep, unbiased research capabilities, making it accessible to laboratories worldwide. The company emphasizes its focus on research use only, with no current diagnostic applications.
Positive
- Seer's Proteograph Product Suite offers advanced proteomic analysis capabilities.
- The upcoming financial results announcement shows transparency and engagement with investors.
Negative
- None.
Details
News Market Reaction – SEER
The recorded move for SEER in the trading session of this news was -4.79%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
REDWOOD CITY, Calif., April 07, 2022 (GLOBE NEWSWIRE) -- Seer Inc. (NASDAQ: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it will report financial results for the first quarter of 2022 on Wednesday, May 4, 2022. Company management will be webcasting a conference call beginning at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time.
Live audio of the webcast will be available on the Investor section of Seer’s website at investor.seer.bio. An archived replay will be available on the company’s website following the event.
About Seer
Seer™ is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph™ Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.
Investor Contact
Carrie Mendivil
investor@seer.bio
Media Contact
Karen Possemato
pr@seer.bio
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.